Showing 3341-3350 of 5646 results for "".
- Glaukos Announces Agreement to Buy Avedro in All-Stock Dealhttps://modernod.com/news/glaukos-announces-agreement-to-buy-avedro-in-all-stock-deal/2479551/In a move to diversify its offerings and expand its corneal health franchise, Glaukos agreed to acquire cross-linking company Avedro in an all-stock transaction.
- Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Anti-Microbial Ophthalmic and Otic Therapeuticshttps://modernod.com/news/harrow-health-forms-stowe-pharmaceuticals-subsidiary-to-develop-anti-microbial-ophthalmic-and-otic-therapeutics/2479553/Harrow Health announced that its newly formed subsidiary, Stowe Pharmaceuticals, has entered into an agreement with TGV Health to acquire worldwide rights to the Zian anti-microbial molecule for ophthalmic and otic uses. Zian is a patented small molecule that is water soluble, colorless,
- Iveric bio Announces Successful Advancement of LCA10 Minigene Program and Expansion of Orphan Gene Therapyhttps://modernod.com/news/iveric-bio-announces-successful-advancement-of-lca10-minigene-program-and-expansion-of-orphan-gene-therapy/2476762/Iveric bio announced that the company has exercised its option and entered into an exclusive global license agreement with the University of Massachusetts Medical School for rights to develop and commercialize mutation independent novel adeno-associated virus (AAV) gene therapy product candidates
- Genentech/Roche Complete Enrollment in Archway Phase 3 Study of the Port Delivery System with Ranibizumab in Wet AMDhttps://modernod.com/news/genentech-roche-complete-enrollment-in-archway-phase-3-study-of-the-port-delivery-system-with-ranibizumab-in-wet-amd/2476737/Genentech and Roche have completed patient enrollment in the phase 3 Archway (
- Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseaseshttps://modernod.com/news/trefoil-therapeutics-raises-28-million-series-a-to-advance-engineered-fgf-1-for-the-treatment-of-corneal-diseases/2476735/Trefoil Therapeutics announced it raised $28 million in an oversubscribed Series A financing. The company is developing novel engineered fibroblast growth factor-1 proteins (eFGF-1) as a regenerative pharmacologic therapy to treat serious corneal endothelial diseases and epithelial disorders.
- Zeiss Marks Milestone for its New North America High Tech Site in Dublin, Californiahttps://modernod.com/news/zeiss-marks-milestone-for-its-new-north-america-high-tech-site-in-dublin-california/2476730/Zeiss announced that it has completed the “steel topping out” phase of its new high tech site in the San Francisco Bay Area. The new center will encompass 208,650 square feet with three floors. It is scheduled for completion in the fourth quarter of 2020 and will bring together multiple Ze
- Market Scope: Booming Demand, Surgical Planning Integration Drive Growth in Ophthalmic Diagnostic Markethttps://modernod.com/news/market-scope-booming-demand-surgical-planning-integration-drive-growth-in-ophthalmic-diagnostic-market/2476723/Market Scope estimates that the ophthalmic diagnostic equipment market will total $3.2 billion in 2019, and the firm expects it to increase to $3.8 billion in 2024—for a compound annual growth rate of 3.9 percent. Contributing factors include a rising global population, with an expanding elderly
- Oxurion NV Reports Topline Phase 1 Results with THR-149 for the treatment of DMEhttps://modernod.com/news/oxurion-nv-reports-topline-phase-1-results-with-thr-149-for-the-treatment-of-dme/2476706/Oxurion NV reported positive topline data from a phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of diabetic macular edema (DME). THR-149 has been developed in partnership with Bicycle Therapeutics. Oxurion holds the exclusive license to the PKal
- New Research Suggests Glaucoma Screening Could Save Three Million Years Of Blindness In Chinahttps://modernod.com/news/new-research-suggests-glaucoma-screening-could-save-three-million-years-of-blindness-in-china/2476692/New research by Orbis International, Queen’s University Belfast, and Wenzhou Medical University has found that offering glaucoma screening in China could be highly cost-effective while reducing blindness among the population. The novel findings could change
- VSY Biotechnology is Now Accepting Applications for the “Ophthalmology Star Awards”https://modernod.com/news/vsy-biotechnology-is-now-accepting-applications-for-the-ophthalmology-star-awards/2476689/The Stars of Ophthalmology will be selected among the applicants who have a scientific article published in an ophthalmology journal since January 2018, according to a VSY Biotechnology news release. The articles are required to be authored in English and already published in order to be eligible